Krystsina Yakubovich/iStock via Getty Images
- Sana Biotechnology (NASDAQ:SANA) said that the U.S. FDA granted Fast Track Designation for SC291, its CAR T therapy for systemic lupus erythematosus.
- The company is currently enrolling patients with B-cell mediated autoimmune diseases in the GLEAM trial. Initial data is expected
